» Articles » PMID: 37305160

Regulation of Pathological Blood-brain Barrier for Intracranial Enhanced Drug Delivery and Anti-glioblastoma Therapeutics

Overview
Journal Oncol Res
Specialty Oncology
Date 2023 Jun 12
PMID 37305160
Authors
Affiliations
Soon will be listed here.
Abstract

The blood-brain barrier (BBB) is an essential component in regulating and maintaining the homeostatic microenvironment of the central nervous system (CNS). During the occurrence and development of glioblastoma (GBM), BBB is pathologically destroyed with a marked increase in permeability. Due to the obstruction of the BBB, current strategies for GBM therapeutics still obtain a meager success rate and may lead to systemic toxicity. Moreover, chemotherapy could promote pathological BBB functional restoration, which results in significantly reduced intracerebral transport of therapeutic agents during multiple administrations of GBM and the eventual failure of GBM chemotherapy. The effective delivery of intracerebral drugs still faces severe challenges. However, strategies that regulate the pathological BBB to enhance the transport of therapeutic agents across the barrier may provide new opportunities for the effective and safe treatment of GBM. This article reviews the structure and function of BBB in physiological states, the mechanisms underlying BBB pathological fenestration during the development of GBM, and the therapeutic strategies of GBM based on BBB intervention and medicinal drugs transporting across the BBB.

Citing Articles

Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.

Maity S, Bhuyan T, Jewell C, Kawakita S, Sharma S, Nguyen H Small. 2024; 21(1):e2405511.

PMID: 39535474 PMC: 11719323. DOI: 10.1002/smll.202405511.


Allogeneic stem cells engineered to release interferon β and scFv-PD1 target glioblastoma and alter the tumor microenvironment.

Vogiatzi I, Moreno Lama L, Lehmann A, Rossignoli F, Gettemans J, Shah K Cytotherapy. 2024; 26(10):1217-1226.

PMID: 38852095 PMC: 11427148. DOI: 10.1016/j.jcyt.2024.05.012.


3D Bioprinting of Neurovascular Tissue Modeling with Collagen-Based Low-Viscosity Composites.

Wang S, Bai L, Hu X, Yao S, Hao Z, Zhou J Adv Healthc Mater. 2023; 12(25):e2300004.

PMID: 37264745 PMC: 11469067. DOI: 10.1002/adhm.202300004.

References
1.
Santhanam L, Christianson D, Nyhan D, Berkowitz D . Arginase and vascular aging. J Appl Physiol (1985). 2008; 105(5):1632-42. PMC: 2584835. DOI: 10.1152/japplphysiol.90627.2008. View

2.
Lalatsa A, Schatzlein A, Uchegbu I . Strategies to deliver peptide drugs to the brain. Mol Pharm. 2014; 11(4):1081-93. DOI: 10.1021/mp400680d. View

3.
Lajoie J, Shusta E . Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2014; 55:613-31. PMC: 5051266. DOI: 10.1146/annurev-pharmtox-010814-124852. View

4.
Wright J, Merchant R . Blood-brain barrier changes following intracerebral injection of human recombinant tumor necrosis factor-alpha in the rat. J Neurooncol. 1994; 20(1):17-25. DOI: 10.1007/BF01057957. View

5.
Hawkins B, Davis T . The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57(2):173-85. DOI: 10.1124/pr.57.2.4. View